Biogen INC BIOGEN INC ORD SHS
Biogen INC BIOGEN INC ORD SHS/ US09062X1037 /
0R1B
|
24/05/2024 18:25:10
|
Chg.
-
|
Volume |
Bid06:00:05 |
Ask06:00:05 |
Market Capitalization |
Dividend Y. |
P/E Ratio |
|
218.75USD
|
-
|
1,014
Turnover: 110,398.48 |
-Bid Size: - |
-Ask Size: - |
25.34 bill.USD |
- |
21.69 |
Business description
Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies.
Management board & Supervisory board
| CEO |
| Christopher A. Viehbacher |
| Management board |
| Michael McDonnell, Dr. Ginger Gregory, Rachid Izzar, Susan H. Alexander, Nicole Murphy, Priya Singhal |
| Supervisory board |
| Caroline Dorsa, Eric K. Rowinsky, Jesus B. Mantas, Maria C. Freire, Stephen A. Sherwin, William A. Hawkins, Susan Langer, Christopher A. Viehbacher, Lloyd B. Minor |
Company data
| Name: |
Biogen Inc. |
| Address: |
225 Binney Street,Cambridge, Massachusetts 02142, USA |
| Phone: |
+1 781-464-2000 |
| Fax: |
+1-617-679-2617 |
| E-mail: |
-
|
| Internet: |
www.biogen.com |
| Industry: |
Biotechnology |
| Sector: |
Biotechnology |
| Sub sector: |
Biotechnology |
| End of financial year: |
31/12 |
| Free Float: |
72.20% |
| IPO date: |
- |
Investor relations
| Name: |
Karen Jewell |
| IR phone: |
781-464-2442 |
| IR Fax: |
- |
| IR e-mail: |
IR@biogenidec.com
|
Main Shareholders
| Others |
|
48.93% |
| PRIMECAP MANAGEMENT CO CA |
|
11.17% |
| Vanguard Group |
|
9.90% |
| BlackRock Inc. |
|
9.79% |
| State Street Corporation |
|
4.77% |
| "T. Rowe Price Investment Management, Inc." |
|
3.68% |
| Wellington Management Group |
|
3.66% |
| JP Morgan Chase & Co. |
|
3.44% |
| GEODE CAPITAL MANAGEMENT LLC |
|
2.27% |
| Others |
|
2.40% |
